Related references
Note: Only part of the references are listed.Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Muhammad S. Beg et al.
INVESTIGATIONAL NEW DRUGS (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation
Maria Angelica Cortez et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates
Kevin Kelnar et al.
ANALYTICAL CHEMISTRY (2014)
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
dsRNA-Activation of TLR3 and RLR Signaling: Gene Induction-Dependent and Independent Effects
Saurabh Chattopadhyay et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2014)
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Christopher L. Daige et al.
MOLECULAR CANCER THERAPEUTICS (2014)
TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1
Jane Zhao et al.
MOLECULAR THERAPY (2013)
MicroRNA-34a Enhances T Cell Activation by Targeting Diacylglycerol Kinase ζ
Jinwook Shin et al.
PLOS ONE (2013)
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
Maria T. Di Martino et al.
CLINICAL CANCER RESEARCH (2012)
Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo
V. J. Craig et al.
LEUKEMIA (2012)
miR-34 – a microRNA replacement therapy is headed to the clinic
Andreas G. Bader
Frontiers in Genetics (2012)
Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1
Vanessa J. Craig et al.
BLOOD (2011)
Developing therapeutic microRNAs for cancer
A. G. Bader et al.
GENE THERAPY (2011)
Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice
Phong Trang et al.
MOLECULAR THERAPY (2011)
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Can Liu et al.
NATURE MEDICINE (2011)
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Andrea L. Kasinski et al.
NATURE REVIEWS CANCER (2011)
SylArray: a web server for automated detection of miRNA effects from expression data
Nenad Bartonicek et al.
BIOINFORMATICS (2010)
The Promise of MicroRNA Replacement Therapy
Andreas G. Bader et al.
CANCER RESEARCH (2010)
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Jason F. Wiggins et al.
CANCER RESEARCH (2010)
The miR-34 family in cancer and apoptosis
H. Hermeking
CELL DEATH AND DIFFERENTIATION (2010)
MicroRNA-34a Perturbs B Lymphocyte Development by Repressing the Forkhead Box Transcription Factor Foxp1
Dinesh S. Rao et al.
IMMUNITY (2010)
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells
Na Li et al.
CANCER LETTERS (2009)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Qing Ji et al.
PLOS ONE (2009)
Alterations in microRNA expression contribute to fatty acid-induced pancreatic β-cell dysfunction
Pascal Lovis et al.
DIABETES (2008)
Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation
Marjorie Robbins et al.
HUMAN GENE THERAPY (2008)
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene
Kristina A. Cole et al.
MOLECULAR CANCER RESEARCH (2008)
Detecting microRNA binding and siRNA off-target effects from expression data
Stijn van Dongen et al.
NATURE METHODS (2008)
p53-mediated activation of miRNA34 candidate tumor-suppressor genes
Guido T. Bommer et al.
CURRENT BIOLOGY (2007)
A microRNA component of the p53 tumour suppressor network
Lin He et al.
NATURE (2007)
MicroRNA signatures in human cancers
George A. Calin et al.
NATURE REVIEWS CANCER (2006)
Oncomirs - microRNAs with a role in cancer
A Esquela-Kerscher et al.
NATURE REVIEWS CANCER (2006)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Share Paper
